REFERENCES
1. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 2008;26:157-67.
2. Patel S, Singh R, Preuss CV, Patel N. Warfarin. In: Treasure island. FL: StatPearls; 2023.
3. Ashorobi D, Ameer MA, Fernandez R. Thrombosis. In: Treasure island. FL: StatPearls; 2023.
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:160S-98S.
5. Rishavy MA, Hallgren KW, Wilson L, Singh S, Runge KW, Berkner KL. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. Blood 2018;131:2826-35.
6. Harutyunyan HA. Prothrombin and fibrinogen carbonylation: how that can affect the blood clotting. Redox Rep 2017;22:160-5.
7. Zermatten MG, Fraga M, Calderara DB, Aliotta A, Moradpour D, Alberio L. Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. JHEP Rep 2020;2:100120.
8. Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of prothrombin time/international normalized ratio (PT/INR). Int J Lab Hematol 2021;43:21-8.
9. Shikdar S, Vashisht R, Bhattacharya PT. International normalized ratio (INR). In: Treasure island. FL: StatPearls; 2023.
10. Al-Momany NH, Makahleh ZM, Al-Omari NA, Al-Sarayreh HA, Momani RO. Analysis of factors that interrupt with INR control in the first anticoagulation clinic monitoring jordanian patients. Clin Appl Thromb Hemost 2019;25:1076029619870252.
11. Elango K, Javaid A, Khetarpal BK, et al. The effects of warfarin and direct oral anticoagulants on systemic vascular calcification: a review. Cells 2021;10:773.
12. Morris R, Luboff H, Jose RP, et al. Bradycardia due to donepezil in adults: systematic analysis of FDA adverse event reporting system. J Alzheimers Dis 2021;81:297-307.
13. Morris R, Umeukeje G, Bu K, Cheng F. The association between use of rivastigmine and pneumonia: systematic analysis of FDA adverse event reporting system. J Alzheimers Dis 2021;83:1061-71.
14. Bu K, Patel D, Morris R, et al. Dysphagia risk in patients prescribed rivastigmine: a systematic analysis of FDA adverse event reporting system. J Alzheimers Dis 2022;89:721-31.
15. Han L, Ball R, Pamer CA, Altman RB, Proestel S. Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system. J Am Med Inform Assoc 2017;24:913-20.
16. Kodani E, Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H. Impact of hemoglobin concentration and platelet count on outcomes of patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM registry. Int J Cardiol 2020;302:81-7.
17. Lim AK, Campbell DA. Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation. Int Urol Nephrol 2013;45:561-70.
18. Donley ER, Munakomi S, Loyd JW. Hemorrhage control. In: Treasure island. FL: StatPearls; 2023.
19. Favaloro EJ, Franchini M, Lippi G. Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review. Semin Thromb Hemost 2014;40:621-33.
20. Mari D, Ogliari G, Castaldi D, Vitale G, Bollini EM, Lio D. Hemostasis and ageing. Immun Ageing 2008;5:12.
21. Amin H, Mohsin S, Aslam M, et al. Coagulation factors and antithrombin levels in young and elderly subjects in Pakistani population. Blood Coagul Fibrinolysis 2012;23:745-50.
22. Ribak G, Barak M, Froom P. Older age is risk for an international normalized ratio (INR) of 5 or more. Clin Lab 2007;53:571-4.
23. Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res 2020;192:40-51.
24. Tsuchida T, Wada T, Nakae R, et al. Gender-related differences in the coagulofibrinolytic responses and long-term outcomes in patients with isolated traumatic brain injury: a 2-center retrospective study. Medicine 2023;102:e32850.
25. Dean L. Warfarin therapy and VKORC1 and CYP genotype. In: Medical genetics summaries. MD: Bethesda; 2012.
26. Fung E, Patsopoulos NA, Belknap SM, et al. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost 2012;38:893-904.
28. Dayoub EJ, Ross JS, Shah ND, Dhruva SS. Evolution of medicare formulary coverage changes for antithrombotic therapies after guideline updates. Circulation 2019;140:1227-30.
29. Wheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician trends in prescribing direct oral anticoagulants for US medicare beneficiaries. JAMA Netw Open 2021;4:e2137288.
30. Makam RCP, Hoaglin DC, McManus DD, et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis. PLoS One 2018;13:e0197583.
31. Lu Y, Shen D, Pietsch M, et al. A novel algorithm for analyzing drug-drug interactions from MEDLINE literature. Sci Rep 2015;5:17357.
32. Lu Y, Figler B, Huang H, Tu YC, Wang J, Cheng F. Characterization of the mechanism of drug-drug interactions from PubMed using MeSH terms. PLoS One 2017;12:e0173548.
33. Lu Y, Ramachandra ACV, Pham M, Tu YC, Cheng F. CuDDI: a CUDA-based application for extracting drug-drug interaction related substance terms from PubMed literature. Molecules 2019;24:1081.
34. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood 2011;118:6269-73.
35. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther Drug Monit 2000;22:742-8.
36. Leong D, Wu PE. Warfarin and acetaminophen interaction in a 47-year-old woman. CMAJ 2020;192:E506-8.
37. Herman LL, Padala SA, Ahmed I, Bashir K. Angiotensin converting enzyme inhibitors (ACEI). In: Treasure island. FL: StatPearls; 2023.
38. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001;103:1746-51.
39. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002;105:457-61.
40. Phillips W, Piller LB, Williamson JD, et al. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. J Clin Hypertens 2013;15:825-32.
41. Huxel C, Raja A, Ollivierre-Lawrence MD. Loop diuretics. In: Treasure island. FL: StatPearls; 2023.
42. Farzam K, Jan A. Beta blockers. In: Treasure island. FL: StatPearls; 2023.
43. Berlowitz DR, Miller DR, Oliveria SA, Cunningham F, Gomez-Caminero A, Rothendler JA. Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. Pharmacoepidemiol Drug Saf 2006;15:799-807.
44. Ma Y, Ma J, Yang J. Association between pre-existing long-term β-blocker therapy and the outcomes of sepsis-associated coagulopathy: a retrospective study. Medicina 2022;58:1843.
45. Mantero F, Procidano M, Vicariotto MA, Girolami A. Effect of atenolol and metoprolol on the anticoagulant activity of acenocoumarin. Br J Clin Pharmacol 1984;17 Suppl 1:94S-6S.
46. Preckel D, von Känel R. Regulation of hemostasis by the sympathetic nervous system: any contribution to coronary artery disease? Heartdrug 2004;4:123-30.
47. Andersson ML, Mannheimer B, Lindh JD. The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. Eur J Clin Pharmacol 2019;75:1387-92.
